<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419964</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-VTL-03(09/11)</org_study_id>
    <nct_id>NCT01419964</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ACH24 in the Treatment of Vitiligo</brief_title>
  <official_title>Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel
      group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of
      achromatic areas in patients with vitiligo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy and safety of ACH24 compared to placebo in the treatment of
      vitiligo.The present study aims to register a new product in the country, the ACH24 for the
      treatment of vitiligo.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The Brazilian regulatory agency - ANVISA has requested the cancellation of the phase 3 study
    for conducting a phase 1 study first.
  </why_stopped>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repigmentation of the affected area assessed by VASI (vitiligo area scoring index).</measure>
    <time_frame>Baseline compared to the end of 18 months of treatment</time_frame>
    <description>It is considered successful treatment a repigmentation of greater than or equal to 50% of the affected area assessed by VASI (vitiligo area scoring index).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Baseline and each 12 weeks of treatment (V0, V3, V6, V9, V12, V15, V18)</time_frame>
    <description>Dermatology Life Quality Index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety descriptive about occurence of adverse events, evaluation of results of general physical examination.</measure>
    <time_frame>Will be evaluated during whole study, at the baseline and after 18 months of treatment</time_frame>
    <description>Collection of safety data throughout the whole study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Group 01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACH24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 02</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 01</intervention_name>
    <description>ACH24</description>
    <arm_group_label>Group 01</arm_group_label>
    <other_name>ACH24</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 02</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group 02</arm_group_label>
    <other_name>PLACEBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes, aged between 18 and 65 years, remaining the feasibility of a
             legal guardian in accordance with need, able to understand and provide written
             informed consent and able to allow compliance at the treatment and the requirements of
             the protocol;

          -  Presence of generalized vitiligo;

          -  Able to comprehend and willing to provide written informed consent in accordance with
             institutional and regulatory guidelines.

        Exclusion Criteria:

          -  Patients with:

               -  Inflammatory diseases;

               -  Alopecia Areata;

               -  Diabetes Type I;

               -  Asthma;

               -  Collagen disease;

               -  Atopic dermatitis;

               -  Psoriasis;

               -  Autoimmune thyroid disease (self reported). ¬ Thyroid problems (represents 15% of
                  people with vitiligo), exclude only those who need to do treatment with
                  corticosteroid or immunosuppressive.

          -  Women of childbearing age who had tested positive for pregnancy, or who do not use
             acceptable contraceptive method, or do not agree to practice reliable contraception
             during the study;

          -  Woman in pregnancy or lactation period;

          -  Known allergic reaction against the phytomedicine as assessed by medical history;

          -  Patient that is taking any prohibited medication (Item 9.3);

          -  Participation in last one year of clinical protocols, unless it can be direct benefit
             to subject;

          -  Any finding of clinical observation (anamnesis and physical exam) laboratory
             abnormality (eg, blood glucose, blood count), disease (for example, liver,
             cardiovascular system, lung) or therapy that, in opinion of the investigator, may
             endanger the subject or interfere with the endpoints of study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CAIO CASTRO, PHYSICIAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>PUNTIFÍCIA UNIVERSIDADE CATÓLICA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80010-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>March 15, 2016</last_update_submitted>
  <last_update_submitted_qc>March 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>Macular depigmentation</keyword>
  <keyword>Stachytarpheta cayensensis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

